Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Croda backs FY profit guidance even as Q1 sales decline

(Sharecast News) - Croda backed its full-year profit guidance on Wednesday despite a decline in first-quarter sales, as it hailed an "encouraging" start to the year for the consumer care business. In an update for the three months to the end of March, the speciality chemicals company said group sales fell 10% at constant currency versus a strong prior year comparator, to £409m. On a reported basis, sales were down 14%.

Compared with the final quarter of 2023, reported sales rose 8% excluding lipid sales for Covid-19 vaccine applications in the previous quarter, and overall group results were "in line with expectations", it said.

Croda said that for 2024, it continues to expect group adjusted operating margin to be two to three percentage points lower than 2023, and adjusted pre-tax profit of between £260m and £300m.

Chief executive Steve Foots said: "Consumer Care has made an encouraging start to the year with growth across all business units and a significant improvement in North America. Life Sciences continues to experience more challenging market conditions, particularly in Crop Protection.

"Overall, we are on track to meet our previously stated group guidance for the full year. We are focused on executing our strategy, accelerating the conversion of our exciting Pharma pipeline, and investing for the future whilst carefully monitoring costs, with a clear set of priorities that will drive our near-term performance."

Share this article

Related Sharecast Articles

Berenberg starts coverage of Just Group at 'buy', highlights attractive business model
(Sharecast News) - Berenberg initiated coverage of Just Group on Tuesday with a 'buy' rating and 209p price target.
Octopus Energy to pay £1.5m for billing errors
(Sharecast News) - Octopus Energy has been told to pay £1.5m in refunds and compensation by the UK's energy regulator after it failed to provide customers with final bills within six weeks.
JPMorgan resumes coverage of Glencore at 'overweight'
(Sharecast News) - JPMorgan Cazenove resumed coverage of Glencore on Tuesday with an 'overweight' rating and 360p price target following a two-year period of restriction relating to Viterra's merger with Bunge Global.
Abu Dhabi sovereign investor to take $100m stake in Revolut - report
(Sharecast News) - Abu Dhabi sovereign investor Mubadala is reportedly in talks buy a $100m (£73m) stake in digital bank and payments group Revolut.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.